The synergistic therapeutic combination of niraparib and either CCR8 or CD25 mAb has exhibited broader applicability and effectiveness in other orthotopic breast cancer mouse models with breast cancer susceptibility gene (BRCA) deficiency, which enlighten a novel immunotarget of eTregs for HRD ovarian cancers. This evidence concerns the gene CCR8 and breast carcinoma.